WINDTREE THERAPEUTICS INC License Agreements
8 Contracts & Agreements
- License, Development and Commercialization Agreement, by and between the Company and Lees Pharmaceutical (HK) Ltd., dated January 12, 2024 (Filed With SEC on April 16, 2024)
- Amendment No. 1, effective as of January 17, 2024, to the License Agreement, between Windtree and Philip Morris Products S.A. dated March 28, 2008 (Filed With SEC on April 16, 2024)
- Amendment No. 1, effective as of January 17, 2024, to the Amended and Restated License Agreement, between Windtree and Philip Morris USA Inc. dated March 28, 2008 (Filed With SEC on April 16, 2024)
- Amended and Restated License, Development and Commercialization Agreement, by and among Lees Pharmaceutical (HK) Ltd., Zhaoke Pharmaceutical (Hefei) Co. Ltd., and Windtree... (Filed With SEC on November 14, 2022)
- Amendment No. 1 dated as of August 14, 2017 to the License Development and Commercialization Agreement by and between the Company and Lees Pharmaceutical (HK) Ltd. dated as of... (Filed With SEC on November 14, 2017)
- LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT by and between windtree therapeutics, inc. and Lee’s pharmaceutical (hk) LTD. Table of Contents (Filed With SEC on August 21, 2017)
- Exhibit 10.5 Confidential Treatment Requested Execution Version LICENSE AGREEMENT by and between DISCOVERY LABORATORIES, INC. (a Delaware corporation) and PHILIP MORRIS PRODUCTS... (Filed With SEC on May 9, 2008)
- AMENDED AND RESTATED LICENSE AGREEMENT by and between DISCOVERY LABORATORIES, INC. (a Delaware corporation) and PHILIP MORRIS USA INC., d/b/a CHRYSALIS TECHNOLOGIES (a Virginia... (Filed With SEC on May 9, 2008)
